证券代码：002370 证券简称：亚太药业 公告编号：2025-094 浙江亚太药业股份有限公司 关于第八届董事会第七次会议决议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、董事会会议通知的时间和方式 浙江亚太药业股份有限公司（以下简称"公司"）第八届董事会 第七次会议（以下简称"会议"）通知于 2025 年 12 月 3 日以专人送 达、微信等方式送达各位董事。 2、召开董事会会议的时间、地点和方式 会议于 2025 年 12 月 8 日在公司办公楼三楼会议室以现场表决与 通讯表决相结合的方式召开。 3、董事会会议出席情况 本次会议的应表决董事 9 人，实际参与表决董事 9 人，其中董事 长宋凌杰先生以通讯方式参与表决，公司监事、高级管理人员列席会 议。 4、会议由副董事长黄小明先生主持。 5、本次会议的通知、召开以及参与表决董事人数均符合相关法 律、法规、规则及《公司章程》的有关规定。 二、董事会会议审议情况 （一）以 9 票同意，0 票反对，0 票弃权，审议通过了《关于修 改<公司章程>的议案》 1 根据《中华人民共 ...

证券日报网讯12月5日，亚太药业（002370）在互动平台回答投资者提问时表示，公司2024年度合并报 表和母公司报表未分配利润均为负值，不满足公司实施现金分红的条件。 ...

浙江亚太药业股份有限公司 简式权益变动报告书 （修订稿） 上市公司名称：浙江亚太药业股份有限公司 股票上市地点：深圳证券交易所 股票简称：亚太药业 股票代码：002370 信息披露义务人：宁波富邦控股集团有限公司 注册地址：宁波市海曙区长春路 2 号 4、5 楼 通讯地址：宁波市鄞州区宁东路 188 号富邦中心 D 座 25 楼 一致行动人：上海汉贵投资管理有限公司 注册地址：上海市崇明区长兴镇潘园公路 152 号 1115 室（上海泰和经济发展区） 通讯地址：上海市崇明区长兴镇潘园公路 152 号 1115 室（上海泰和经济发展区） 股份变动性质：股份减少（协议转让） 签署日期：2025 年 11 月 27 日 1 信息披露义务人及其一致行动人声明 一、信息披露义务人根据《中华人民共和国公司法》《中华人民共和国证券 法》《上市公司收购管理办法》《公开发行证券公司信息披露内容与格式准则第 15 号—权益变动报告书》及相关法律法规编写本报告书。 二、本报告书已全面披露信息披露义务人在浙江亚太药业股份有限公司拥有 权益的股份变动情况。截至本报告书签署日，除本报告书披露的信息外，信息披 露义务人没有通过其他任何方式 ...

浙江亚太药业股份有限公司详式权益变动报告书 浙江亚太药业股份有限公司 详式权益变动报告书 （二次修订稿） 上市公司名称：浙江亚太药业股份有限公司 股票上市地点：深圳证券交易所 一、本报告书系根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第15号 ——权益变动报告书》《公开发行证券的公司信息披露内容与格式准则第16号— —上市公司收购报告书》及相关的法律法规和部门规章的有关规定编制。 二、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定，本报 告书已全面披露信息披露义务人及其一致行动人在浙江亚太药业股份有限公司拥 有权益的股份变动情况。 截至本报告书签署日，除本报告书披露的信息外，信息披露义务人及其一致行 动人没有通过任何其他方式在浙江亚太药业股份有限公司拥有的权益。 三、信息披露义务人及其一致行动人签署本报告书已获得必要的授权和批准， 其履行亦不违反其合伙协议或内部规则中的任何条款，或与之相冲突。 股票简称：亚太药业 股票代码：002370 信息披露义务人：浙江星浩控股合伙企业（有限合伙） 住所：浙江省湖州市安吉县灵峰街道清远 ...

证券代码：002370 证券简称：亚太药业 公告编号：2025-092 浙江亚太药业股份有限公司 关于控股股东及其一致行动人签署《股份转让协议之补 充协议》暨控制权拟发生变更的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、协议转让情况概述 2025 年 10 月 13 日，公司控股股东宁波富邦控股集团有限公 司（以下简称"富邦集团"）及一致行动人上海汉贵投资管理有限公 司（以下简称"汉贵投资"）与浙江星浩控股合伙企业（有限合伙） （以下简称"星浩控股"）、浙江星宸股权投资合伙企业（有限合伙） （以 下简称"星宸投资"）签署了《股份转让协议》。富邦集团和 汉 贵 投 资 拟 通 过 协 议 转 让 方 式 转 让 公 司 14.61% 股 份 ， 共 计 108,945,566 股，转让价格为 8.26 元/股，合计总金额为 90,000.00 万元，其中星浩控股受让富邦集团持有的公司 60,525,314 股股份， 星宸投资受让富邦集团、汉贵投资分别持有的公司 28,894,686 股股 份、19,525,566 股股份。本次协议转让完成后，公 ...

国联民生证券承销保荐有限公司 关于 浙江亚太药业股份有限公司 详式权益变动报告书 之 财务顾问核查意见 （二次修订稿） 二〇二五年十一月 国联民生承销保荐财务顾问核查意见 声 明 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司收 购管理办法》《公开发行证券的公司信息披露+内容与格式准则第15号——权益 变动报告书》《公开发行证券的公司信息披露内容与格式准则第16号——上市 公司收购报告书》等法律法规的规定，国联民生证券承销保荐有限公司按照证 券行业公认的业务标准、道德规范和勤勉尽责精神，对本次信息披露义务人披 露的《浙江亚太药业股份有限公司详式权益变动报告书》进行核查，并出具核查 意见。 为使相关各方恰当地理解和使用本核查意见，本财务顾问特别声明如下： 1、本财务顾问已按照规定履行了尽职调查义务，对信息披露义务人披露的 《详式权益变动报告书》进行了核查，确信披露文件内容与格式符合规定，并保 证所发表的专业意见与信息披露义务人披露内容不存在实质性差异； 2、本财务顾问所依据的有关资料由信息披露义务人提供。信息披露义务人 已做出声明，保证其所提供的所有文件、材料及口头证言真实、准确、完整、及 时， ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.44% on November 19, with Hainan Haiyao leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Shanhe Pharmaceutical (300452) with a closing price of 15.07, up 9.04% and a trading volume of 390,200 shares, totaling 586 million yuan [1] - ST Suhao (600200) closed at 1.02, up 5.15% with a trading volume of 429,200 shares [1] - ST Jingfeng (000908) closed at 66.8, up 5.02% with a trading volume of 354,800 shares [1] - Major decliners included: - Muan Nanhai (000566) with a closing price of 7.20, down 10.00% and a trading volume of 2,192,500 shares, totaling 1.625 billion yuan [2] - Sitaili (603520) closed at 10.66, down 6.74% with a trading volume of 315,600 shares [2] - Yatai Pharmaceutical (002370) closed at 7.79, down 6.59% with a trading volume of 1,044,700 shares [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 2.278 billion yuan from institutional investors, while retail investors contributed a net inflow of 2.139 billion yuan [2] - The top stocks by net inflow from institutional investors included: - Changshan Pharmaceutical (300255) with a net inflow of 71.90 million yuan, accounting for 6.20% of total inflow [3] - Xingqi Eye Medicine (300573) with a net inflow of 70.33 million yuan, representing 12.29% [3] - Shanhe Pharmaceutical (300452) with a net inflow of 68.13 million yuan, making up 11.62% [3]

Group 1 - The chemical pharmaceutical sector increased by 0.83% on November 12, with Asia-Pacific Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] - Key stocks in the chemical pharmaceutical sector showed significant gains, with Asia-Pacific Pharmaceutical rising by 5.90% to a closing price of 868 [1] Group 2 - The chemical pharmaceutical sector experienced a net inflow of 656 million yuan from institutional investors, while retail investors saw a net outflow of 804 million yuan [2][3] - Major stocks like Heng Rui Medicine and Bai Jie Shen Zhou had notable net inflows from institutional investors, indicating strong interest [3] - The trading volume and turnover for various stocks in the sector varied, with significant activity noted in stocks like Fu Xiang Pharmaceutical and Ri Ji Shen [1][2]

Core Viewpoint - Zhejiang Yatai Pharmaceutical Co., Ltd. is undergoing a strategic transformation from generic drugs to innovative drug development, supported by new leadership and funding for research projects [1][2][4]. Group 1: Company Overview - Yatai Pharmaceutical is a well-established pharmaceutical company in China with a complete pharmaceutical business chain, offering a wide range of products including anti-infectives, antiviral, digestive system, and cardiovascular drugs [1]. - As of September 2025, the company holds 114 approved drug formulations, with 19 products passing consistency evaluations and 3 products entering national centralized procurement [1]. Group 2: Financial Performance - In the first three quarters, Yatai Pharmaceutical achieved revenue of approximately 228 million yuan and a net profit of about 97.2 million yuan, marking a significant year-on-year increase of 2,909.49% [1]. Group 3: Strategic Changes - The company plans to change its actual controller to Mr. Qiu Zhongxun, the chairman and founder of Yaodou Technology, and will raise 700 million yuan through a private placement to fund new drug research projects [1][3]. - This transition signifies a shift towards innovative drug development, moving away from a focus on generic drugs [2][6]. Group 4: Innovation and R&D Focus - Yatai Pharmaceutical's innovation strategy includes developing oncolytic virus drug platforms and long-acting complex formulations, targeting a market expected to reach 160 billion yuan by 2025 in China and the U.S. [2]. - The company adopts a balanced approach to R&D, focusing on specific disease areas while ensuring sustainable new drug development and efficient use of funds [2]. Group 5: Market and Policy Environment - The new leadership and strategic focus align with favorable national policies promoting biomanufacturing and innovative drug development as key economic growth areas [4][5]. - The recent launch of the national drug research major project is expected to enhance the drug innovation ecosystem in China, benefiting companies like Yatai Pharmaceutical [5]. Group 6: Market Performance - Yatai Pharmaceutical's stock has seen a significant increase, with a year-to-date rise of over 178%, reflecting investor confidence in the company's innovative transformation [3][6]. - Analysts predict that the successful implementation of the new funding projects will lead to a revaluation of the company, transitioning it from a traditional generic drug firm to an innovative drug platform company [6].

Core Insights - On November 11, Asia-Pacific Pharmaceutical Co., Ltd. saw a stock increase of 1.68% with a trading volume of 1.127 billion yuan [1] - The company reported a financing buy-in amount of 83.81 million yuan and a net financing buy of 1.10 million yuan on the same day [1][2] - As of November 11, the total financing and securities lending balance for the company was 291 million yuan, which is 4.61% of its market capitalization [1] Financing Summary - The financing buy-in for Asia-Pacific Pharmaceutical on November 11 was 83.81 million yuan, with a current financing balance of 291 million yuan, indicating a high level compared to the past year [1] - The financing balance exceeds the 90th percentile level over the past year, indicating a strong position in the market [1] Securities Lending Summary - On November 11, there were no shares repaid or sold in the securities lending market, with a total lending balance of 0.00 yuan, also indicating a high level compared to the past year [1] Company Overview - Asia-Pacific Pharmaceutical Co., Ltd. was established on December 31, 2001, and listed on March 16, 2010 [1] - The company specializes in pharmaceutical manufacturing, including the research, production, and sales of chemical preparations and raw materials [1] - The revenue composition includes 56.49% from antibiotic preparations, 42.84% from non-antibiotic preparations, and 0.67% from other sources [1] Financial Performance - As of September 30, the number of shareholders increased to 91,500, a rise of 66% compared to the previous period [2] - The average number of circulating shares per person decreased by 39.76% to 8,152 shares [2] - For the period from January to September 2025, the company reported a revenue of 22.8 million yuan, a decrease of 25.59% year-on-year, while the net profit attributable to the parent company was 97.20 million yuan, a significant increase of 2909.49% [2] Dividend Information - Since its A-share listing, Asia-Pacific Pharmaceutical has distributed a total of 186 million yuan in dividends, with no dividends paid in the last three years [3]